Format

Send to

Choose Destination
Adv Drug Deliv Rev. 2018 Feb 1;125:102-121. doi: 10.1016/j.addr.2018.01.011. Epub 2018 Feb 2.

Clinical applications of the CellSearch platform in cancer patients.

Author information

1
Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
2
Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
3
Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: pantel@uke.de.

Abstract

The CellSearch® system (CS) enables standardized enrichment and enumeration of circulating tumor cells (CTCs) that are repeatedly assessable via non-invasive "liquid biopsy". While the association of CTCs with poor clinical outcome for cancer patients has clearly been demonstrated in numerous clinical studies, utilizing CTCs for the identification of therapeutic targets, stratification of patients for targeted therapies and uncovering mechanisms of resistance is still under investigation. Here, we comprehensively review the current benefits and drawbacks of clinical CTC analyses for patients with metastatic and non-metastatic tumors. Furthermore, the review focuses on approaches beyond CTC enumeration that aim to uncover therapeutically relevant antigens, genomic aberrations, transcriptional profiles and epigenetic alterations of CTCs at a single cell level. This characterization of CTCs may shed light on the heterogeneity and genomic landscapes of malignant tumors, an understanding of which is highly important for the development of new therapeutic strategies.

KEYWORDS:

Breast cancer; CellSearch®; Circulating tumor cells (CTCs); Gastrointestinal tumors; Lung cancer; Molecular characterization of single CTCs; Urological tumors

PMID:
29355669
DOI:
10.1016/j.addr.2018.01.011

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center